Clinical applications of palifermin: amelioration of oral mucositis and other potential indications

Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT

(2015) Barbara Nasilowska-Adamska et al.   Annals of Transplantation

Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients With Cancer

(2013) Saroj Vadhan-Raj   ANNALS OF INTERNAL MEDICINE

Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

(2012) Muneer H. Abidi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase I Study of the Tolerability and Pharmacokinetics of Palifermin in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

(2012) Ashok Srinivasan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

(2012) Muneer H. Abidi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden

(2012) N Blijlevens et al.   BONE MARROW TRANSPLANTATION

Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial

(2012) M H Jagasia et al.   BONE MARROW TRANSPLANTATION

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants

(2012) J D Goldberg et al.   BONE MARROW TRANSPLANTATION

Peritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation

(2011) Romee Rizwan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study

(2011) Quynh-Thu Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial

(2011) Michael Henke et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer

(2011) Wolfgang Schuette et al.   Journal of Thoracic Oncology

Keratinocyte growth factor enhanced immune reconstitution in murine allogeneic umbilical cord blood cell transplant

(2011) Yi Wang et al.   LEUKEMIA & LYMPHOMA

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma

(2010) G. Kobbe et al.   ANNALS OF ONCOLOGY

Palifermin-induced acral erythrodysaesthesia variant in the treatment of acute myeloid leukaemia

(2010) Olivia Milne et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

A Phase 1 Dose-Escalation Study To Evaluate The Safety And Pharmacokinetics Of Palifermin In Pediatric Subjects With Acute Leukemias Undergoing Myeloablative Therapy And Allogeneic Hematopoietic Stem Cell Transplant

(2010) J. Morris et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Evaluation of current and upcoming therapies in oral mucositis prevention

(2010) Jerry C Wu et al.   Future Oncology

Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation

(2009) R. M. Kelly et al.   BLOOD

Combination of radiotherapy and chemotherapy in locally advanced NSCLC

(2009) Lucyna Kepka et al.   Expert Review of Anticancer Therapy

Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis

(2008) E. Schmidt et al.   ANNALS OF ONCOLOGY

Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

(2008) John E. Levine et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation

(2008) R. R. Jenq et al.   BLOOD

Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation

(2008) R. M. Kelly et al.   BLOOD

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients

(2008) S Langner et al.   BONE MARROW TRANSPLANTATION

Palifermin in allogeneic HSCT: many questions remain

(2008) W J F M van der Velden et al.   BONE MARROW TRANSPLANTATION

Prevalence of Outpatient Cancer Treatment in the United States: Estimates from the Medical Panel Expenditures Survey (MEPS)

(2008) Michael T. Halpern et al.   CANCER INVESTIGATION

Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma

(2008) David M. Brizel et al.   JOURNAL OF CLINICAL ONCOLOGY